(Q37798928)

23 August 2017

title

Public vaccination programmes against hepatitis B in The Netherlands: assessing whether a targeted or a universal approach is appropriate (English)

1 reference

23 August 2017

0 references

Hans Houweling

1

1 reference

23 August 2017

Christiaan F W Wittevrongel

2

1 reference

23 August 2017

Marcel Verweij

3

1 reference

23 August 2017

E Joost Ruitenberg

4

1 reference

23 August 2017

National Immunisation Programme Review Committee of the Health Council of the Netherlands

5

1 reference

23 August 2017

language of work or name

English

0 references

publication date

14 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

28

1 reference

23 August 2017

issue

49

1 reference

23 August 2017

page(s)

7723-7730

1 reference

23 August 2017

cites work

Hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Criteria for inclusion of vaccinations in public programmes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Molecular epidemiology of acute hepatitis B in the Netherlands in 2004: nationwide survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

The e antigen and vertical transmission of hepatitis B surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Model based analysis of hepatitis B vaccination strategies in the Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Hepatitis B vaccination targeted at behavioural risk groups in the Netherlands: does it work?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Impact of a targeted hepatitis B vaccination program in Amsterdam, The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Molecular sequence data of hepatitis B virus and genetic diversity after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Vaccination against hepatitis B in low endemic countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Hepatitis B virus infection: epidemiology and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

Parental attitude towards childhood HBV vaccination in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.068

10.1016/J.VACCINE.2010.09.068

7 January 2021

Identifiers

DOI

1 reference

23 August 2017

1 reference